A clinician-level review of dulaglutide (Trulicity) use in patients with autoimmune conditions, covering thyroid disease, IBD, lupus, RA, and safety signals from REWIND and post-marketing data.
A guide to discontinuing Trulicity (dulaglutide), covering tapering strategies, rebound hyperglycemia risk, medication transitions, and what to monitor after your last dose.
A week-by-week guide to dulaglutide (Trulicity) in your first month: side effects, blood sugar changes, dosing milestones, and what the evidence from REWIND and AWARD trials actually shows.
Dulaglutide (Trulicity) is not FDA-approved for NAFLD or MASLD, but trial data suggest it reduces hepatic fat and liver enzymes in patients with type 2 diabetes. Learn what the evidence shows, how it is dosed, and who may benefit.
A guide to using dulaglutide (Trulicity) for prediabetes: off-label rationale, dosing, trial evidence from REWIND and AWARD studies, side effects, and how to talk to your doctor.
A guide to dulaglutide (Trulicity) safety in adults aged 65 and older, covering renal function, falls risk, GI tolerability, drug interactions, cardiovascular evidence from REWIND, and deprescribing thresholds.
A guide to how state Medicaid programs generally handle Trulicity (dulaglutide) coverage, prior authorization, step therapy, and appeals for type 2 diabetes and, in some states, weight management. State rules vary and require direct verification.
A clinician-level guide to dulaglutide (Trulicity) pharmacogenomics, covering GLP-1R variants, TCF7L2 genotype effects, metabolic enzyme polymorphisms, cardiovascular outcomes by ancestry, and how genetic testing might one day personalize GLP-1 therapy.
A guide to using dulaglutide (Trulicity) after bariatric surgery, covering pharmacokinetics, dosing, evidence from REWIND and other trials, and practical prescribing considerations for post-bariatric patients with type 2 diabetes.
A guide to dulaglutide (Trulicity) use during pregnancy and breastfeeding, covering FDA labeling, animal data, GLP-1 receptor biology, and evidence-based alternatives for managing type 2 diabetes in reproductive-age women.
A clinician-level guide to switching between dulaglutide (Trulicity) and other GLP-1 receptor agonists, covering dose conversion, washout timing, cardiovascular evidence from REWIND, and practical injection guidance.
A week-by-week guide to the first 30 days on dutasteride (Avodart) for BPH and hair loss. Covers DHT suppression timelines, shedding phases, side effects, and what your lab work should show.
A guide to dutasteride (Avodart) safety in men aged 65 and older, covering renal function, falls risk, drug interactions, cardiovascular signals, and deprescribing criteria.
Avodart (dutasteride) info for ages 50-64: half-life, DHT suppression, REDUCE trial prostate cancer data, sexual side effects, and drug interaction risks.
A clinician-level review of empagliflozin (Jardiance) and cancer risk signals, covering EMPA-REG OUTCOME, FAERS pharmacovigilance data, FDA labeling history, and current prescribing guidance.
A clinician-level review of empagliflozin's long-term cardiovascular effects, covering EMPA-REG OUTCOME, EMPEROR-Reduced, EMPEROR-Preserved, mechanism of action, and practical prescribing guidance.
A deep dive into empagliflozin (Jardiance) and its known effects on hair, skin, and related dermatologic conditions, including genital mycotic infections, urinary changes, and rare rash reports.
Jardiance and anesthesia: hold empagliflozin 3 to 4 days before general or neuraxial anesthesia to cut euglycemic DKA risk; restart 24 to 48 hours post-op.
A guide to monitoring enclomiphene citrate therapy in men aged 30, 49, covering lab schedules, dose adjustments, safety endpoints, and when to stop treatment.
A clinical guide to Anthem (Elevance Health) coverage, prior authorization criteria, step therapy requirements, and appeal strategies for enclomiphene citrate prescriptions.
A clinician-level review of enclomiphene citrate use in patients with autoimmune disease, covering pharmacology, immune-axis interactions, trial data, and practical prescribing guidance for secondary hypogonadism.
A clinical and insurance guide to Cigna coverage, prior authorization, step therapy, and appeal strategies for enclomiphene citrate prescriptions. prepared by the HealthRX.com Editorial Team.
A GRADE-graded review of every major enclomiphene citrate trial, covering testosterone restoration, spermatogenesis, and how the evidence compares to clomiphene and exogenous TRT for secondary hypogonadism.
A comprehensive clinical review of enclomiphene citrate for secondary hypogonadism: how it works, what the trial data show, dosing protocols, side effects, and who qualifies for treatment.
A comprehensive look at the origins, chemistry, clinical trials, and regulatory path of enclomiphene citrate, the trans-isomer of clomiphene with a distinct mechanism for treating secondary hypogonadism while preserving fertility.
A deep dive into how enclomiphene citrate affects liver enzymes, hepatic metabolism, and long-term liver safety, with primary-literature citations throughout.
A state-by-state guide to Medicaid coverage, prior authorization, step therapy, and appeal strategies for enclomiphene citrate prescribed for secondary hypogonadism.
A deep dive into enclomiphene citrate microdosing protocols for secondary hypogonadism, covering clinical trial data, dose-titration strategies, monitoring parameters, and how microdosing compares to standard dosing.
A guide to enclomiphene citrate off-label uses, covering secondary hypogonadism, male infertility, PCOS, and more, with evidence grades, named trials, doses, and primary-source citations.
A guide to monitoring enclomiphene citrate in adults aged 50, 64, covering lab schedules, cardiovascular risk, polypharmacy, and dose adjustments for secondary hypogonadism.
A clinical review of enclomiphene citrate safety for men ages 50 to 64, covering cardiovascular risk, polypharmacy interactions, dosing, monitoring protocols, and what current evidence says about long-term use in the andropause window.
A deep dive into enclomiphene citrate's mechanism, patent history, FDA regulatory status, and when a generic version is realistically expected.
An evidence-based deep dive into enclomiphene citrate pharmacokinetics covering absorption, protein binding, CYP-mediated metabolism, half-life, and clinical relevance for treating secondary hypogonadism.
A clinician-level review of enclomiphene citrate real-world evidence, including registry data, RWE studies, mechanism of action, dosing, and how it compares to TRT for secondary hypogonadism.
Evidence-based guide to storing enclomiphene citrate correctly, understanding its chemical stability, and knowing when compounded preparations expire.
A clinician-level guide to switching between enclomiphene citrate, clomiphene, tamoxifen, anastrozole, and TRT for secondary hypogonadism, with pharmacology, protocols, and evidence-based transition timelines.
A complete clinical guide to monitoring enclomiphene citrate in men aged 18, 29 with secondary hypogonadism, covering lab schedules, fertility preservation, dose adjustments, and safety checkpoints prepared by the HealthRX.com Editorial Team.
A week-by-week guide to enclomiphene citrate for secondary hypogonadism: expected testosterone changes, symptom timelines, lab targets, and dose-adjustment checkpoints for the first 30 days.
A clinical and insurance guide explaining Aetna's current coverage position on epitalon, prior-authorization steps, appeal pathways, and cash-pay alternatives for patients seeking this tetrapeptide.
A step-by-step guide to Aetna (CVS Health) oral estradiol coverage, formulary tier, prior authorization criteria, step therapy requirements, and how to appeal a denial.
A complete guide to Anthem (Elevance Health) coverage for oral estradiol, including formulary tiers, prior authorization criteria, step therapy requirements, appeal strategies, and out-of-pocket cost options.
A clinical review of how oral estradiol affects appetite, food cravings, and body weight in menopausal women, with an honest account of what trial evidence does and does not support.
A clinical and insurance guide covering Blue Cross Blue Shield Federated formulary tiers, prior authorization criteria, step therapy, appeals, and out-of-pocket cost for oral estradiol for menopausal vasomotor symptoms.
A clinical deep-dive into how oral estradiol affects bone mineral density, fracture risk, and skeletal outcomes in menopausal women, with primary-literature citations and dosing guidance.
A complete guide to Cigna's coverage policy for oral estradiol, including formulary tier, prior authorization criteria, step therapy requirements, and how to appeal a denial.
A week-by-week guide to oral estradiol for menopausal vasomotor symptoms: what changes to expect, when to expect them, and how to interpret your first 30 days on therapy.
A guide to oral estradiol for perimenopause: FDA approval status, dosing protocols, trial evidence, side effects, and how to start treatment safely.
Evidence-based guide to oral estradiol dosing in patients aged 65 and older, covering starting doses, titration, safety monitoring, drug interactions, and when to consider deprescribing.
A complete guide to Humana's coverage of oral estradiol for menopausal vasomotor symptoms, including formulary tiers, prior authorization criteria, step therapy requirements, appeal strategies, and cost alternatives.
A guide to Kaiser Permanente's formulary status, prior authorization rules, step therapy requirements, and appeal process for oral estradiol (estrace, generic 17β-estradiol tablets).
A state-by-state breakdown of Medicaid coverage for oral estradiol, including prior authorization criteria, step therapy requirements, formulary tiers, and how to appeal a denial.
A guide to how oral estradiol affects mood, depression, anxiety, and cognitive function in perimenopausal and postmenopausal women, with trial data, dosing context, and practical guidance.
A deep dive into oral estradiol pharmacokinetics, covering absorption, first-pass metabolism, distribution, hepatic conversion, and clinical implications for HRT dosing.
How seasonal factors, including temperature swings, UV exposure, vitamin D status, and circadian shifts, affect oral estradiol dosing, absorption, and hot-flash burden. Evidence-based guidance for clinicians and patients.
A guide to using oral estradiol in transplant recipients, people living with HIV, older adults, and other special populations. Covers drug interactions, dose adjustments, and evidence-based monitoring.
A complete guide to UnitedHealthcare coverage for oral estradiol, including formulary tier, prior authorization criteria, step therapy requirements, appeal steps, and out-of-pocket cost options.
A guide to how Aetna (CVS Health) commercial and Medicare plans typically handle estradiol patch coverage, prior authorization, and step therapy, with a framework for deciding how to approach an appeal.
A guide to Anthem (Elevance Health) formulary status, prior authorization criteria, step therapy requirements, and appeal strategies for estradiol transdermal patches.
Does the estradiol patch change appetite and food cravings? A deep dive into the clinical evidence, mechanisms, trial data, and what patients can expect.
A clinical and insurance guide to Blue Cross Blue Shield coverage of estradiol transdermal patches, including how formulary tiers, prior authorization, and step therapy actually work across BCBS's independently operated member companies, and how to appeal a denial.